Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation and Depletion: 2022-2024

Historic Depreciation and Depletion for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $300,000.

  • Centessa Pharmaceuticals' Depreciation and Depletion fell 47.83% to $48,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $300,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $300,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Depreciation and Depletion of $300,000 as of FY2024, which was down 0.00% from $300,000 recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Depreciation and Depletion peaked at $300,000 during FY2023, and registered a low of $131,000 during FY2022.
  • Moreover, its 3-year median value for Depreciation and Depletion was $300,000 (2024), whereas its average is $243,667.
  • Data for Centessa Pharmaceuticals' Depreciation and Depletion shows a peak YoY soared of 129.01% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Centessa Pharmaceuticals' Depreciation and Depletion stood at $131,000 in 2022, then spiked by 129.01% to $300,000 in 2023, then remained steady at $300,000 in 2024.